Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

@article{Wang2019TreatmentRelatedAE,
  title={Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.},
  author={Yucai Wang and S. Zhou and F. Yang and Xinyue Qi and X. Wang and Xiaoxiang Guan and C. Shen and N. Duma and Jesus Vera Aguilera and A. Chintakuntlawar and K. Price and J. Molina and L. Pagliaro and T. Halfdanarson and A. Grothey and S. Markovic and G. Nowakowski and S. Ansell and M. Wang},
  journal={JAMA oncology},
  year={2019}
}
  • Yucai Wang, S. Zhou, +16 authors M. Wang
  • Published 2019
  • Medicine
  • JAMA oncology
  • Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice. Objective To evaluate the incidences of treatment-related adverse events of PD-1 and PD-L1 inhibitors and the differences between different drugs and cancer types. Data Sources PubMed, Web of Science, Embase, and Scopus were searched from October 1… CONTINUE READING
    126 Citations
    Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.
    • D. Magee, A. Hird, +4 authors G. Kulkarni
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2020
    • 11

    References

    SHOWING 1-10 OF 138 REFERENCES
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    • 8,320
    • PDF
    Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    • J. Brahmer, C. Drake, +17 authors S. Topalian
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 2,107
    Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    • 559
    Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    • D. McDermott, J. Sosman, +11 authors T. Powles
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2016
    • 387
    Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    • C. Massard, M. Gordon, +16 authors N. Segal
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2016
    • 488
    • PDF